about
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer TherapyTargeting Oncogenic Mutant p53 for Cancer TherapyThe p53-estrogen receptor loop in cancerOxidative Stress Resistance in Metastatic Prostate Cancer: Renewal by Self-EatingThe rebel angel: mutant p53 as the driving oncogene in breast cancer.p53 as a Regulator of Lipid Metabolism in CancerNovel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cellsMutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.A tree shrew glioblastoma model recapitulates features of human glioblastomaEffects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cellsRapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73.Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts.Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1α-TWIST signaling networks in human breast cancer cellsDown-regulation of the antisense mitochondrial non-coding RNAs (ncRNAs) is a unique vulnerability of cancer cells and a potential target for cancer therapy.An aqueous extract of Fagonia cretica induces DNA damage, cell cycle arrest and apoptosis in breast cancer cells via FOXO3a and p53 expression.Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women.Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growthGain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.ΔNp63α expression induces loss of cell adhesion in triple-negative breast cancer cells.Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.Kaiso depletion attenuates the growth and survival of triple negative breast cancer cellsTherapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).p53 inhibits the expression of p125 and the methylation of POLD1 gene promoter by downregulating the Sp1-induced DNMT1 activities in breast cancer.The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.Regulator of G protein signaling 6 is a novel suppressor of breast tumor initiation and progressionMutant p53-Notch1 Signaling Axis Is Involved in Curcumin-Induced Apoptosis of Breast Cancer Cells.p53 signaling is involved in leptin-induced growth of hepatic and breast cancer cells.Death inducing and cytoprotective autophagy in T-47D cells by two common antibacterial drugs: sulphathiazole and sulphacetamideGenetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies.Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.The effects of turmeric (curcumin) on tumor suppressor protein (p53) and estrogen receptor (ERα) in breast cancer cells.New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy.Mutant p53 in cancer: new functions and therapeutic opportunities.The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
P2860
Q24337757-338096E1-66C7-47DC-8DFD-9D6174FF5E0EQ26770856-205D8AFF-9F8F-41BE-9940-217163546202Q27027865-2D648805-565E-4626-9C82-2641B15F3419Q27334935-F36212B7-E897-4A0E-A39D-0A0AD4620443Q27686765-C3F0A0C3-8923-4C12-9906-4D79CFEB6516Q28079393-C305B8DB-4984-4346-93AA-0A8944262156Q28259152-F7A98EC6-2765-45AF-B315-1FBCA532099EQ30537354-C8B88EBC-BF25-4904-BF6F-AC9AF98D9251Q33566729-E9D425B2-4F96-45DE-A50A-AA90EBF7A15EQ33605964-B5E1609B-51FC-4F02-A163-3E50EBF953DBQ33649918-F5AE1C2D-0B08-4DB9-A39A-51862D8CC6EEQ33657418-9DC0D9AF-0D79-4BE2-937A-EAD9E6265844Q34054835-2F3E8233-0EBB-46E4-BEBA-9A1C9907751AQ34245117-A68BA56B-15B7-4667-9E1A-DB40E5FE5CF2Q34326755-6192E99D-0A51-4179-9692-86FCFF5CB2D7Q34421158-03DAE7BB-43AC-49CB-BABA-957C5B7220DCQ34566248-144CD35A-E8C7-471F-B6CF-110787C17E2DQ35073239-68F0B97A-A6A8-4089-9B80-A450C3C56C37Q35626610-67741DA3-666A-442F-9BEE-FA843DCF0C66Q36056465-1DF58EB1-47E4-4D99-8602-EDA20FE5C133Q36070462-BFA3DE5C-D758-4E05-940B-D896EE563810Q36159875-FCBA208E-A1A0-4D29-B276-50FB113E6520Q36289944-6246A41E-C2B9-4827-B455-ACC94DD50811Q36293880-0DBA1E00-3EAC-410A-A1AB-0A46D61A2E35Q36309603-76ACEA1A-3F37-4B94-B217-6BDCE73D32A8Q36319385-1009145D-AE47-46AA-B7CA-11D0F9917F1CQ36640056-07FC5C3B-27D8-4B55-80CB-A1E32AEA90FAQ36688072-E36E6921-87C7-45BA-A00D-5E17F0F19CC4Q36766027-0A6EE312-5548-41B5-B3F5-A4C414AF1BB1Q36905671-EDC7F6B2-C642-4B33-A74D-72FF0E85C870Q37065354-8685484A-69CF-4E78-BD62-16ED4E130C4CQ37090089-4448006D-9597-4AD6-ABCE-1514A0E9CCD7Q37239773-7179B224-0597-4958-A7A5-2A20834B9130Q37281885-548F1037-3818-4FAE-8567-F09205C4C336Q37317404-B207EBC6-3DFA-41CF-AAC3-056162B04BBFQ37628912-A9819F65-3BEF-4F27-9DDE-40A718F07A23Q37705673-0E4DCA85-FD02-42B1-A94F-2B1A0BF21473Q38036571-B4790EF3-CE39-4DA6-947C-7EB8CCE81DCAQ38197826-E7BB1074-89E2-425C-9A90-1A0891AE545AQ38926422-0A49459E-7AB3-49C2-A2B8-162BC9450DBA
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mutant p53 mediates survival of breast cancer cells
@en
Mutant p53 mediates survival of breast cancer cells.
@nl
type
label
Mutant p53 mediates survival of breast cancer cells
@en
Mutant p53 mediates survival of breast cancer cells.
@nl
prefLabel
Mutant p53 mediates survival of breast cancer cells
@en
Mutant p53 mediates survival of breast cancer cells.
@nl
P2093
P2860
P356
P1476
Mutant p53 mediates survival of breast cancer cells
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605335
P407
P577
2009-09-22T00:00:00Z